Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ACADEMIA
ACADEMIA
- US Journal Corrects COI Disclosure to Clarify Involvement of Shionogi and Eli Lilly Japan in Paper on “Pain in Depression”
April 23, 2014
- JSBMR’s Guidelines Recommend Alendronate, Risedronate as First-Line Therapies for Steroid-Induced Osteoporosis Based on Available Data
April 22, 2014
- Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
- JSH Publishes New Hypertension Guidelines
April 3, 2014
- Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data
March 26, 2014
- Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher
March 25, 2014
- Revised Treatment Guidelines for HER2-Positive Gastric Cancer Will Recommend Combination Therapy with Trastuzumab
March 25, 2014
- Current Tax Rules for Medical Fees Unreasonable, Litigation an Option: Major Hospital Chain
March 25, 2014
- Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
- NCNP Research Group Confirms Efficacy of Tocilizumab for Neuromyelitis Optica
March 19, 2014
- Japan Hematology Society to Open Probe into SIGN Trial
March 19, 2014
- Lead Author to Revise COI Statement in Article Used to Promote Antidepressant Cymbalta
March 19, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- JSH Guidelines to Strongly Recommend Beta Blockers for Patients with Certain Complications
March 18, 2014
- University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
- National University Hospitals to Disclose Funding from Autumn, but with Company Names Withheld
March 11, 2014
- JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- NCNP to Begin Investigator-Initiated Trial of Multiple Sclerosis Treatment
February 28, 2014
- Japan Diabetes Society Crosses Out SMART Study from Its Guidelines
February 25, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…